# A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants Ages 4-11 Years Old With Persistent Asthma

> **NCT02040766** · PHASE3 · COMPLETED · sponsor: **Teva Branded Pharmaceutical Products R&D, Inc.** · enrollment: 628 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Beclomethasone dipropionate BAI
- **DRUG:** Placebo BAI
- **DRUG:** albuterol/salbutamol 90 mcg
- **DRUG:** Beclomethasone dipropionate MDI
- **DRUG:** Placebo MDI

## Key facts

- **NCT ID:** NCT02040766
- **Lead sponsor:** Teva Branded Pharmaceutical Products R&D, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12
- **Primary completion:** 2016-02
- **Final completion:** 2016-03
- **Target enrollment:** 628 (ACTUAL)
- **Last updated:** 2021-11-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02040766

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02040766, "A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants Ages 4-11 Years Old With Persistent Asthma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02040766. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*